Last reviewed · How we verify
Propionyl-L-carnitine Tablets
Propionyl-L-carnitine is a carnitine derivative that may improve blood flow and reduce oxidative stress.
Propionyl-L-carnitine is a carnitine derivative that may improve blood flow and reduce oxidative stress. Used for Intercritical and progressive forms of multiple sclerosis, Atherosclerosis, Erectile dysfunction.
At a glance
| Generic name | Propionyl-L-carnitine Tablets |
|---|---|
| Also known as | DROMOS, ST261 |
| Sponsor | Lee's Pharmaceutical Limited |
| Drug class | carnitine derivative |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Propionyl-L-carnitine is thought to exert its effects by increasing the levels of L-carnitine in the body, which can help to improve blood flow and reduce oxidative stress. This may be beneficial for conditions such as intermittent claudication and erectile dysfunction.
Approved indications
- Intercritical and progressive forms of multiple sclerosis
- Atherosclerosis
- Erectile dysfunction
- Intermittent claudication
Common side effects
- Gastrointestinal disorders
- Headache
- Fatigue
- Dizziness
Key clinical trials
- Propionyl-L-Carnitine in Ulcerative Colitis (PHASE2)
- Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study (PHASE3)
- Efficacy, Safety and Tolerability of Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis (PHASE3)
- A Single-dose Escalation Safety and PK Study for PLC in Healthy Chinese (PHASE1)
- A Clinical Study on Efficacy & Safety Profile of Propionyl-L-carnitine Tablets for Peripheral Arterial Diseases (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propionyl-L-carnitine Tablets CI brief — competitive landscape report
- Propionyl-L-carnitine Tablets updates RSS · CI watch RSS
- Lee's Pharmaceutical Limited portfolio CI